Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 19/20 | 0.57 |
| ▸ | TCF7L2 | Q9NQB0 | 19/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7255659 | 0.86 | CTNNB1 (0.72) | CTNNB1TCF7L2PDE4APDE4BPDE4C | |
| SCHEMBL7259546 | 0.78 | KMT5A (0.59) | CTNNB1TCF7L2 | |
| SCHEMBL7255656 | 0.77 | HRH4 (0.64) | CTNNB1TCF7L2PDE4APDE4BPDE4C | |
| SCHEMBL3642575 | 0.76 | CTNNB1 (0.68) | CTNNB1TCF7L2PDE4APDE4BPDE4C | |
| SCHEMBL3644763 | 0.76 | PDE5A (0.65) | CTNNB1TCF7L2PDE4APDE4BPDE4C | |
| SCHEMBL7259303 | 0.75 | KMT5A (0.55) | CTNNB1TCF7L2 | |
| SCHEMBL2592377 | 0.74 | PDE5A (0.77) | CTNNB1TCF7L2PDE4APDE4BPDE4C | |
| SCHEMBL3639211 | 0.74 | PDE5A (0.77) | CTNNB1TCF7L2PDE4APDE4BPDE4C | |
| SCHEMBL3643545 | 0.73 | CTNNB1 (0.66) | CTNNB1TCF7L2 | |
| SCHEMBL4175982 | 0.73 | CTNNB1 (1.00) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |